CardioSource WorldNews August 2015 | Page 30

CLINICAL NEWS American College of Cardiology Extended Learning After AF Ablation, Keep Patients on Warfarin Until … O ver the past decade, catheter ablation has emerged as a potential cure for AF, although sometimes the procedure needs to be performed multiple times for long-term effectiveness. One of the most important questions related to this therapy remains unanswered: does long-term maintenance of SR after successful catheter ablation eliminate stroke risk in patients with AF, thus permitting discontinuation of oral anticoagulation therapy (OAT)? Without a well-studied answer to that question, two recent expert consensus documents recommend continuing OAT indefinitely, at least in patients at high risk of thromboembolic events (TE).1,2 Nevertheless, it remains controversial and some centers implement a policy of withdrawing OAT even in the majority of patients at high risk of TE (17% of 42 centers worldwide surveyed in a recent questionnaire). BEST DATA TO DATE, BUT… Themistoclakis and colleagues reported an evaluation of 3,355 patient records from five well-known AF ablation centers.3 In 2,692 patients (~80%), OAT was discontinued 3